119th Congress · House
HR. 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
committee
Introduced 2025-02-06•Latest 2025-02-06
Origin chamber
House
Cosponsors
0
Latest action
Referred to the House Committee on Energy and Commerce.
Subjects
Drug safety, medical device, and laboratory regulationHealthPrescription drugs
Key actions
- Introduced in House
- Introduced in House
- Referred to the House Committee on Energy and Commerce.
Bill text versions
Related bills
No related bills listed.